A knowledge-based company's director of business development, Ali Aqajani, stated, "This year we have gained access to a very new generation of antibody medicines which were exclusively in the hand of a British company."
Pars Today claims that this company has successfully developed anti-cancer medications using antibody-based ADC technology.

With the use of targeted therapy, this technology delivers medication to the malignant tissue and provides the doctor with a medication that combines immunotherapy and chemotherapy.

"This medication, called Tederox, is used to treat breast cancer and certain digestive cancers," Aqajani continued. It can prolong the lives of cancer patients significantly, and because of focused therapy, less medication is administered to the body, preventing common side effects like weight loss or hair loss. Lastly, we will see increased efficacy."

"We are currently in the phase of mass production of this medicine and the price is less than %10 of the foreign brand," he said, highlighting the new medication's noteworthy ability to prevent cancer recurrence. We provide the medication at $200, whereas the overseas sample costs $3000.